Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Europe Viral Vector Manufacturing Market Outlook

The global viral vector manufacturing market size was valued at USD 2.6 billion in 2023, with Europe holding a significant market share. The market is driven by advancements in gene therapy and vaccine development. It is expected to grow at a CAGR of 19.74% during the forecast period of 2024-2032, with the values likely to attain USD 13.5 billion by 2032.

Key Takeaways

  • According to the Alliance for Regenerative Medicine, around 358 gene therapy trials were reported in Europe in 2023, with the total investment in gene therapy estimated to be USD 1.2 billion in the year. The rising focus on gene therapy to treat various diseases is expected to directly impact the market demand.
  • The key market players are actively investing in the capacity expansion of their production facilities which is likely to boost Europe viral vector manufacturing market share in coming years. In June 2023, Yposkesi, the viral vector manufacturing subsidiary of SK pharmteco’s (a CDMO) in France, completed its second facility for the manufacture of cell and gene therapies.
  • A major market trend is the rise in strategic partnerships between the leading biotechnology companies and contract development and manufacturing organizations (CDMOs). In December 2023, Oxford Biomedica entered into an agreement to acquire ABL Europe S.A.S. from Institut Mérieux SA.

Europe Viral Vector Manufacturing Market Analysis

Viral vectors are increasingly used in research settings to deliver genetic material into cells. They are considered the most effective means to transfer genes, to modify a certain cell type or tissue and manipulate them to produce therapeutic proteins. Besides their application in gene therapy and vaccine development, viral vectors are also being explored in other medical fields such as regenerative medicine, immuno-oncology, and neurological disorders. To accommodate these emerging applications, many pharmaceutical and biotechnology companies are investing to expand their production capabilities, which is expected to significantly contribute to the Europe viral vector manufacturing market growth.

The market is witnessing increased demand for viral vectors, which can be attributed to the growing impetus on gene therapy to treat various diseases. According to the Alliance for Regenerative Medicine (an international advocacy organization working to advance safe and effective regenerative cell therapies), around 358 gene therapy trials were reported in Europe in 2023, with the total investment in gene therapy estimated to be USD 1.2 billion  in the year. Thus, to meet the growing demand for gene therapy and keep up with the rising advancements, companies involved in viral vector manufacturing are continuously working towards improving production efficiency and capacity, which is likely to elevate the Europe viral vector manufacturing market value.

In June 2023, the global contract development and manufacturing organization (CDMO) SK pharmteco’s Yposkesi, the viral vector manufacturing subsidiary in France announced the completion of its second facility for the manufacture of cell and gene therapies, particularly specialized for adeno-associated virus (AAV) and lentiviral vectors (LVs) production. Located in the Genopole Campus, the facility is designed with the current (Good Manufacturing Practices) GMP guidelines of Europe and the United States and spans an area of 5,000 square meters. Following the construction of the second cell and gene therapy production, Yposkesi now functions in an area of 10,000 square meters together with the first bioproduction site. The facility will amplify production capacity and help expand the company’s presence in the anti-cancer and immune cell therapy market. Such increased investments to boost production capacity by the major market players is anticipated to augment market share in the coming year.

One of the major Europe viral vector manufacturing market trends is the increased merger and acquisition activities among the leading companies to establish their presence in international markets. In December 2023, Oxford Biomedica (gene and cell therapy biotech company) entered into an agreement to acquire ABL Europe S.A.S. (a pure-play European CDMO) from Institut Mérieux SA (a French holding biotechnology company). The transaction, completed in January 2024, will provide Oxford Biomedica with multi-viral vector CDMO capabilities across multiple sites in the European Union, United States, and United Kingdom as well as offer new facilities in France to improve service for its customers by addressing the demand for process development. Additionally, the acquisition will strengthen the company’s position as the leading cell and gene therapy CDMO. The rise in such strategic partnerships is poised to bolster market growth in the forecast period.

Europe Viral Vector Manufacturing Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup Categories
Type Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, Retroviral Vectors, Others
Application Gene Therapy, Cell Therapy, Vaccines
Therapeutic Area Oncological Disorders, Neurological Disorders, Metabolic Disorders, Immunological Disorders, Others
End User Research Organizations, Biotech and Pharmaceutical Companies, Others
Country United Kingdom, Germany, France, Italy, Others

Europe Viral Vector Manufacturing Market: Competitor Landscape

The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Lonza Group AG
  • Merck KGaA
  • Oxford Biomedica
  • Novartis AG
  • Sartorius AG
  • SIRON Biotech
  • PlasmidFactory GmbH
  • Kaneka Eurogentec S.A.
  • Advanced BioScience Laboratories, Inc.
  • F. Hoffmann-La Roche AG

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Application
  • Therapeutic Area
  • End User
  • Region
Breakup by Type
  • Adenoviral Vectors
  • Adeno-Associated Viral (AAV) Vectors 
  • Lentiviral Vectors
  • Retroviral Vectors
  • Others
Breakup by Application
  • Gene Therapy
  • Cell Therapy
  • Vaccines
Breakup by Therapeutic Area
  • Oncological Disorders
  • Neurological Disorders
  • Metabolic Disorders
  • Immunological Disorders
  • Others 
Breakup by End User
  • Research Organizations
  • Biotech and Pharmaceutical Companies
  • Others
Breakup by Region
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Lonza Group AG
  • Merck KGaA
  • Oxford Biomedica
  • Novartis AG
  • Sartorius AG
  • SIRON Biotech
  • PlasmidFactory GmbH
  • Kaneka Eurogentec S.A.
  • Advanced BioScience Laboratories, Inc. 
  • F. Hoffmann-La Roche AG

Viral Vector Manufacturing Market Report Snapshots

Viral Vector Manufacturing Market Size

Viral Vector Manufacturing Market Analysis

Viral Vector Manufacturing Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The Europe viral vector manufacturing market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 19.74% during the forecast period of 2024-2032 and is likely to reach a market value of USD 13.5 billion by 2032. 

The increasing focus on gene therapy and vaccine development is fuelling the demand for the market.

One of the significant trends in the market is the rise in strategic partnerships between the leading biotechnology companies and contract development and manufacturing organizations (CDMOs). In December 2023 , Oxford Biomedica entered into an agreement to acquire ABL Europe S.A.S. from Institut Mérieux SA. The acquisition will strengthen the company’s position as the leading cell and gene therapy CDMO. 

Based on the type, the market is segmented into adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, and retroviral vectors, among others.

By therapeutic area, the market is divided into oncological disorders, neurological disorders, metabolic disorders, and immunological disorders, among others.

End users of the market are research organizations, biotech, and pharmaceutical companies, among others.

Major applications of viral vector manufacturing include gene therapy, cell therapy, and vaccines.

The market segmentation by countries includes the United Kingdom, Germany, France, and Italy, among others.

The key players in the market are Lonza Group AG, Merck KGaA, Oxford Biomedica, Novartis AG, Sartorius AG, SIRON Biotech, PlasmidFactory GmbH, Kaneka Eurogentec S.A., Advanced BioScience Laboratories, Inc., and F. Hoffmann-La Roche AG.

Purchase Full Report

Datasheet

 

USD 2,639

USD 2,299

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 4,399

USD 3,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 5,829

USD 4,899

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 6,929

USD 5,899

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124